Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.

BACKGROUND A randomised double-blind placebo-controlled phase II study was done to assess the efficacy of a prophylactic quadrivalent vaccine targeting the human papillomavirus (HPV) types associated with 70% of cervical cancers (types 16 and 18) and with 90% of genital warts (types 6 and 11). METHODS 277 young women (mean age 20.2 years [SD 1.7]) were randomly assigned to quadrivalent HPV (20 microg type 6, 40 microg type 11, 40 microg type 16, and 20 microg type 18) L1 virus-like-particle (VLP) vaccine and 275 (mean age 20.0 years [1.7]) to one of two placebo preparations at day 1, month 2, and month 6. For 36 months, participants underwent regular gynaecological examinations, cervicovaginal sampling for HPV DNA, testing for serum antibodies to HPV, and Pap testing. The primary endpoint was the combined incidence of infection with HPV 6, 11, 16, or 18, or cervical or external genital disease (ie, persistent HPV infection, HPV detection at the last recorded visit, cervical intraepithelial neoplasia, cervical cancer, or external genital lesions caused by the HPV types in the vaccine). Main analyses were done per protocol. FINDINGS Combined incidence of persistent infection or disease with HPV 6, 11, 16, or 18 fell by 90% (95% CI 71-97, p<0.0001) in those assigned vaccine compared with those assigned placebo. INTERPRETATION A vaccine targeting HPV types 6, 11, 16, 18 could substantially reduce the acquisition of infection and clinical disease caused by common HPV types.

[1]  I. Frazer,et al.  Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. , 1991, Virology.

[2]  A. Giuliano,et al.  A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. , 2004, Vaccine.

[3]  J. Peto,et al.  The cervical cancer epidemic that screening has prevented in the UK , 2004, The Lancet.

[4]  A. Glass,et al.  The health care costs of cervical human papillomavirus--related disease. , 2004, American journal of obstetrics and gynecology.

[5]  F. X. Bosch,et al.  Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. , 2003, Journal of the National Cancer Institute. Monographs.

[6]  G. Krogh.  Management of anogenital warts (condylomata acuminata). , 2001 .

[7]  Thomas C Wright,et al.  2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities. , 2002, Journal of lower genital tract disease.

[8]  C. Wheeler,et al.  A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.

[9]  I. Krantz,et al.  Symptomatic genital papillomavirus infection in a community , 1996, Acta obstetricia et gynecologica Scandinavica.

[10]  K. Jansen,et al.  Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. , 1997, The Journal of infectious diseases.

[11]  Laura Kann,et al.  Youth risk behavior surveillance--United States, 2003. , 2004, Morbidity and mortality weekly report. Surveillance summaries.

[12]  J. Dillner,et al.  Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. , 1996, Virology.

[13]  I. Chan,et al.  Exact power and sample size for vaccine efficacy studies , 1998 .

[14]  Kathrin U. Jansen,et al.  Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex Assay , 2003, Clinical Diagnostic Laboratory Immunology.

[15]  Mark Sherman,et al.  The 2001 Bethesda System: terminology for reporting results of cervical cytology. , 2002, JAMA.

[16]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[17]  Claude Fauquet,et al.  Classification of papillomaviruses. , 2004, Virology.

[18]  M. Schiffman,et al.  Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. , 2001, JAMA.

[19]  R. Maw,et al.  An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle , 1998, International journal of STD & AIDS.

[20]  C. Wheeler,et al.  Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. , 2004, Vaccine.

[21]  Wendy Macdowall,et al.  Sexual behaviour in Britain: early heterosexual experience , 2001, The Lancet.

[22]  N. Christensen,et al.  Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. , 1996, Virology.

[23]  C. Wheeler,et al.  Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. , 2001, The Journal of infectious diseases.

[24]  Wendy Macdowall,et al.  Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours , 2001, The Lancet.

[25]  M. Schiff,et al.  Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. , 2004, Vaccine.

[26]  C. Wheeler,et al.  Priming of Human Papillomavirus Type 11-Specific Humoral and Cellular Immune Responses in College-Aged Women with a Virus-Like Particle Vaccine , 2002, Journal of Virology.